Skip to main content
 
Haematology Education Centre
Agrylin Product Information
Public information
  

References

  1. Pescatore SL et al. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Exp Opin Pharmacother 2000; 1(3): 537–546.
  2. Agrylin Package Insert. USA, July 2008. Shire US Inc.
  3. Mazur EM et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79(8): 1931–1937.
  4. Wang G et al. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 2005; 146(3): 324–332.
  5. Thiele J et al. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003; 88(10): 1130–1138.
  6. Petrides PE. Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost 2006; 32: 399-408.
  7. Kaushansky K.The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115(12): 3339–3347.
  8. Harrison CN. Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncol 2005; 1(5): 609–618.
  9. Hong Y et al. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets 2002;13(7):381-6.
  10. Hong Y et al. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006;20(6):1117-22.
  11. Silverstein MN et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318(20):1292-4.
  12. Thiele J et al. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 2005;20(4):1071-6.
  13. Birgegård G et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004;89(5):520-7.
  14. Andersson BS. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. Hematology 2002;7(3):173-7.
  15. Birgegård G et al. Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost 2006;32:260-66.
  16. Petrides PE et al. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61(2):71-6.
  17. Boogaerts M, the Anagrelide Study Group. Efficacy of anagrelide in essential thrombocythemia (ET) patients who failed or are intolerant to previous cytoreductive therapy. Blood 2003;103:33a.
  18. Gugliotta L et al. Anagrelide treatment in 167 patients with essential thrombocythaemia: a retrospective study of the Italian group GIMMC. 8th Congress of the European Hematology Association 2003.
  19. Kornblihtt LI et al. Treatment of essential thrombocythaemia with anagrelide: a ten-year experience. Medicina (B Aires) 2002;62(3):231-6.
  20. Silverstein MN et al. The Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76
  21. Fruchtman SM et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29(5):481-91
  22. Giralt M et al. Spanish registry of essential thrombocythemia. Presented at 11th Congress of the European Hematology Association 2006. Abstract 0974.  Retrieved  8 August 2007 from parthen-impact database, on the World Wide Web: http://www.eventure-online.com/eventure/publicAbstractView.do?id=15731
  23. Storen EC et al. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97(4):863-6.
  24. Mazzucconi MG et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004;89(11):1306-13.
  25. Fruchtman SM et al. Anagrelide therapy significantly reduces disease related symptoms in patients with myeloproliferative disorders. Blood 2003;102(11):32a-33a.
  26. Steurer M et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.  Cancer 2004;101(10):2239-46.
  27. Laguna MS et al. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6(3):157-61.
  28. Petitt RM et al.  Assessing the benefit/risk balance of long-term anagrelide hydrochloride (Xagrid/Agrylin) treatment for essential thrombocythaemia. Blood 2005;106:Abstract 4957.
  29. Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5(8):1781-98
Shire
© 2010 Shire Pharmaceuticals Limited
Hampshire International Business Park
Chineham, Basingstoke, Hampshire RG24 8EP
Registered in England 2031674

Agrylin® is a registered trademark of Shire LLC.
Privacy Policy | Terms of Use | Unsubscribe

This website is intended for an international audience.